🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Learn about #BrainMetastases prevalence by therapy line and incidence of #BreastCancerBrainMetastases in this just published cohort study in JNCI. 👉pubmed.ncbi.nlm.nih.gov/40163696/ Dr Sarah Sammons Timothy Erick, PhD Filippo Montemurro Sara Tolaney #JosePabloLeone Nancy Lin, MD

“Even though we are not giving out the results at this time, they are statistically significant and clinically meaningful.” -CMO PFS to beat is 7.5 months, which is a low bar for 1st line therapy. Awaiting results with hope for better options for our patients with TNBC.

While this is likely great progress for our pts, a critical eye is warranted due to impact of continuous ADC obviating maintenance which has excellent QOL. 1) Are we curing more pts? 2) Is OS improved? 3) How are pts feeling? 4) What about ER+ pts (Patina)

Newly Updated ASCO Guideline on Sentinel Lymph Node Biopsy in Early-Stage #BreastCancer, read the full set of recommendations here: 🔓pubmed.ncbi.nlm.nih.gov/40209128/ ✍️Dr.Clara Park, MD, FACS Alison conlin Lynn T. Dengel Brittany Harvey Alastair M Thompson Mylin Torres in Journal of Clinical Oncology

Congratulations to Anne Keane (Anne Keane) one of our #BreastCancer patient advocates, who completed her 4th #BostonMarathon on Monday and raised research funds for Dana-Farber. Thank you, Anne!! 🙏 #StageIVneedsMores #BreastCancerMets #MBC Dr Sarah Sammons Nancy Lin, MD Boston Marathon

Most viewed in the last 7 days from JAMA Oncology: Cooling and compression were highly effective and significantly reduced the risk of high-grade chemotherapy-induced peripheral neuropathy. ja.ma/4iRRte9

Such an important talk on how to evaluate and treat older adults with breast cancer by Rachel Freedman, MD, MPH - evaluation with geriatric assessments can be very helpful to guide us Dana-Farber’s Breast Oncology Center MD Education VIRGINIA KAKLAMANI

Check out the #BreastCancer Research Digest - a summary of last week’s publications from select high-impact journals (April 21st-27th, 2025). #ClinicalResearch #CancerTreatment #BCSM #BreastCancerResearch

What is 20-yr risk of metastatic recurrence in Stage 1A Estrogen +, HER2- breast cancer patients after five years of tamoxifen or AI? 10-17%. (Pan, NEJM 2017) Endocrine therapy lowers risk of recurrence by 47%, so you can do the math for those who do not take it. #bcsm

Caring for #OlderAdultsWithCancer – A Geriatrician’s Role. Watch this short video to learn how Tammy Hshieh, MD, MPH, describes her role as a #geriatrician caring for older patients Dana-Farber. Dr. Hshieh co-manages patients’ care with Dana-Farber’s oncologists, and helps

A simple move, a big impact: Giving IV magnesium before cisplatin cut kidney injury risk by 20%! Safe. Cheap. Available. JAMA Oncology OncoAlert Oncology Brothers LARVOL jamanetwork.com/journals/jamao…

Setting boundaries is not a display of disrespect. It’s an expression of self-respect. Declining a request is not a decision to let others down. It’s a commitment to stand up for yourself. Saying no is not an admission of selfishness. It’s an act of self-preservation.

New paper in JNCI 👉Development of a Multi-Institutional Dataset to Validate a Novel #InflammatoryBreastCancer Diagnostic Score. 👉pubmed.ncbi.nlm.nih.gov/40163681/ Filipa Lynce, MD, FASCO 🇵🇹 🇺🇸 Reshma Jagsi Ginny Mason Susie Sun jennifer bellon Laura Warren, MD Wendy Woodward MDPhD #IBC

Our patients have spoken. They want more community and connection and to explore interventions that may improve their wellbeing outside of their treatments like massage, exercise, acupuncture etc. Dana-Farber’s Breast Oncology Center and Zakim Center for integrative therapies present:

STEM graduate programs must radically rethink science communication training. It’s no longer enough to just present at scientific conferences - students must learn to engage the public effectively, counter misinformation, and confront conspiracy theories head-on.

I wish this was TCHP x 6 versus TDXd x 6 which would have been more relevant to US practice patterns which already avoid anthracyclines. While TCHP is incredibly toxic and I am eager to replace, if compelling, we will be escalating to 8 neoadj cycles vs 6. #bcsm

Rita Nanda Dr Sarah Sammons There is an ongoing randomized neoadjuvant T-DXd vs TCHP trial for HER2+ eBC, though it’s a phase 2 (WSG-ADAPT-HER2-IV). ascopubs.org/doi/10.1200/JC…

Which role for ADCs in CNS malignancies? Have a look! EANO SNO OncoAlert OncoDaily mdpi.com/2072-6694/17/9…

An IDMC is a group of independent experts who monitor the safety, and critical efficacy endpoints of a trial. Example of functional scientific methods, trying to advance breast cancer cures but keep patients safe. Bravo to all involved. This is how we build trust. #bcsm

This is extremely important work that has been needed for 30 years. Well done to Matteo Lambertini, MD PhD and colleagues! #bcsm #Oncology #medtwitter #MedX